首页> 外文期刊>The Journal of Urology >Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
【24h】

Novel targeted pro-apoptotic agents for the treatment of prostate cancer.

机译:用于前列腺癌治疗的新型靶向促凋亡剂。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: We reviewed and highlighted novel targeted apoptotic mediated therapies that can be used to treat prostate cancer. MATERIALS AND METHODS: A comprehensive review of the peer reviewed literature in the area of apoptosis was performed with special emphasis on apoptotic mediated pathways with promising novel targeted therapies that can be used for patients with prostate cancer. RESULTS: The apoptotic pathway can be classified into 2 separate broad categories, including the extrinsic and the intrinsic pathways. Targeting the extrinsic or intrinsic mediated pathway holds promise for developing novel agents for treating prostate cancer. We discuss apoptosis related molecules and therapies, as categorized by 1) targeting apoptosis pathway for antitumor treatment, 2) targeting apoptosis regulators for antitumor treatment and 3) drugs that potentiate pro-apoptotic agents. CONCLUSIONS: Defining the molecules responsible for apoptosis and their intricate molecular interactions will help guide us in developing drugs with less toxicity for appropriately selected patients with prostate cancer and other malignancies. Because neoadjuvant and adjuvant clinical trials are under way using novel pro-apoptotic agents for prostate cancer, it is imperative for urologists to be active members of the clinical research team and become familiar with the molecular pathways, and potential benefits and toxicities associated with these novel agents.
机译:目的:我们回顾并重点介绍了可用于治疗前列腺癌的新型靶向凋亡介导疗法。材料与方法:对细胞凋亡领域的同行评议文献进行了全面回顾,特别强调了凋亡介导的途径,并提出了可用于前列腺癌患者的有希望的新型靶向疗法。结果:凋亡途径可分为两大类,包括外在途径和内在途径。靶向外在或内在的介导途径,有望为开发治疗前列腺癌的新型药物。我们讨论了与凋亡相关的分子和疗法,归类为:1)靶向凋亡途径进行抗肿瘤治疗; 2)靶向凋亡调节剂进行抗肿瘤治疗;以及3)增强促凋亡药物的药物。结论:定义负责细胞凋亡的分子及其复杂的分子相互作用将有助于指导我们为适当选择的前列腺癌和其他恶性肿瘤患者开发毒性更小的药物。由于新辅助疗法和辅助性临床试验正在使用新型促凋亡剂治疗前列腺癌,因此泌尿科医师必须成为临床研究团队的积极成员,并熟悉分子途径以及与这些新型疗法相关的潜在益处和毒性代理商。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号